HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (“GAD”) expected in Q1 2026 -
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and ExecutionFormer President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLC Proven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programs Appointed as Helus Pharma advances its […]
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and ExecutionThis news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
